Clinical research into chronic graft-versus-host disease (GVHD) lags behind that in other areas in the field. Interest in chronic GVHD has increased significantly in recent years for various reasons, including advances in biotechnology, a perceived increase in the incidence of chronic GVHD, and decreased regimen-related mortality, resulting in a new emphasis on quality of life and absence of disability as endpoints of major significance in transplantation survivors. In this overview, we address 3 key areas related to chronic GVHD that hold the highest promise for major advances in the near future: pathobiology, response criteria, and therapy.
No takes yet. Share an insight, caveat, or question.
Shlomchik et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: